These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 8651950)

  • 21. Cyclosporine A-induced increase in glomerular cyclic GMP in rats and the involvement of the endothelinB receptor.
    Tack I; Marin-Castano E; Bascands JL; Pecher C; Ader JL; Girolami JP
    Br J Pharmacol; 1997 Jun; 121(3):433-40. PubMed ID: 9179384
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis.
    Thomas SE; Andoh TF; Pichler RH; Shankland SJ; Couser WG; Bennett WM; Johnson RJ
    Kidney Int; 1998 Apr; 53(4):897-908. PubMed ID: 9551396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of drug transporter inhibitors on the pharmacokinetics and tissue distribution of methotrexate in normal and tumor-bearing mice: a microdialysis study.
    Sani SN; Henry K; Böhlke M; Kim J; Stricker-Krongrad A; Maher TJ
    Cancer Chemother Pharmacol; 2010 May; 66(1):159-69. PubMed ID: 19816684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model.
    Khezrian M; Sheikholeslami B; Dadashzadeh S; Lavasani H; Rouini M
    Cancer Chemother Pharmacol; 2015 May; 75(5):961-8. PubMed ID: 25757960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.
    Raschko JW; Synold TW; Chow W; Coluzzi P; Hamasaki V; Leong LA; Margolin KA; Morgan RJ; Shibata SI; Somlo G; Tetef ML; Yen Y; ter Veer A; Doroshow JH
    Cancer Chemother Pharmacol; 2000; 46(5):403-10. PubMed ID: 11127945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo microdialysis with LC-MS for analysis of spinosin and its interaction with cyclosporin A in rat brain, blood and bile.
    Ma RH; Yang J; Qi LW; Xin GZ; Wang CZ; Yuan CS; Wen XD; Li P
    J Pharm Biomed Anal; 2012 Mar; 61():22-9. PubMed ID: 22169469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
    Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
    J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance.
    Le Bot MA; Kernaleguen D; Robert J; Berlion M; Riché C
    Cancer Chemother Pharmacol; 1994; 35(1):53-8. PubMed ID: 7987977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption.
    Leu BL; Huang JD
    Cancer Chemother Pharmacol; 1995; 35(5):432-6. PubMed ID: 7850926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CYP4A/CYP2C modulation of the interaction of calcium channel blockers with cyclosporine on EDHF-mediated renal vasodilations in rats.
    Hammoud SH; Omar AG; Eid AA; El-Mas MM
    Toxicol Appl Pharmacol; 2017 Nov; 334():110-119. PubMed ID: 28899749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of endothelin receptor antagonist on cyclosporine-induced vasoconstriction in isolated rat renal arterioles.
    Lanese DM; Conger JD
    J Clin Invest; 1993 May; 91(5):2144-9. PubMed ID: 8486781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia.
    Dahl GV; Lacayo NJ; Brophy N; Dunussi-Joannopoulos K; Weinstein HJ; Chang M; Sikic BI; Arceci RJ
    J Clin Oncol; 2000 May; 18(9):1867-75. PubMed ID: 10784627
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of Long-Lasting Oatp Inhibition by Typical Inhibitor Cyclosporine A and In Vitro-In Vivo Discrepancy in Its Drug Interaction Potential in Rats.
    Taguchi T; Masuo Y; Kogi T; Nakamichi N; Kato Y
    J Pharm Sci; 2016 Jul; 105(7):2231-9. PubMed ID: 27290622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can celecoxib affect P-glycoprotein-mediated drug efflux? A microPET study.
    de Vries EF; Doorduin J; Vellinga NA; van Waarde A; Dierckx RA; Klein HC
    Nucl Med Biol; 2008 May; 35(4):459-66. PubMed ID: 18482683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo evidence for ATP-dependent and P-glycoprotein-mediated transport of cyclosporin A at the blood-brain barrier.
    Sakata A; Tamai I; Kawazu K; Deguchi Y; Ohnishi T; Saheki A; Tsuji A
    Biochem Pharmacol; 1994 Nov; 48(10):1989-92. PubMed ID: 7986214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers.
    Xin HW; Wu XC; Li Q; Yu AR; Zhong MY; Liu YY
    Methods Find Exp Clin Pharmacol; 2006; 28(1):25-9. PubMed ID: 16541194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bradykinin receptor agonist facilitates low-dose cyclosporine-A protection against 6-hydroxydopamine neurotoxicity.
    Borlongan CV; Emerich DF; Hoffer BJ; Bartus RT
    Brain Res; 2002 Nov; 956(2):211-20. PubMed ID: 12445688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.
    Boote DJ; Dennis IF; Twentyman PR; Osborne RJ; Laburte C; Hensel S; Smyth JF; Brampton MH; Bleehen NM
    J Clin Oncol; 1996 Feb; 14(2):610-8. PubMed ID: 8636778
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tissue distribution and in vivo immunosuppressive activity of liposomal cyclosporine.
    Vadiei K; Lopez-Berestein G; Perez-Soler R; Luke DR
    Drug Metab Dispos; 1991; 19(6):1147-51. PubMed ID: 1687023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia.
    List AF; Spier C; Greer J; Wolff S; Hutter J; Dorr R; Salmon S; Futscher B; Baier M; Dalton W
    J Clin Oncol; 1993 Sep; 11(9):1652-60. PubMed ID: 8102639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.